MedTrace Logo

Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

NCT00503139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 684

Last updated 2017-02-28

Study results available
· View outcomes & findings →

Summary

The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives: 1. To examine the safety of long-term use of Enbrel including the occurrence of malignant tumors. 2. To confirm the efficacy of Enbrel in the long-term use.

Conditions

Interventions

DRUG

Enbrel (etanercept)

Enbrel 10 to 25 mg twice a week subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503139 on ClinicalTrials.gov